<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="134586">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02034279</url>
  </required_header>
  <id_info>
    <org_study_id>INFECIR 2</org_study_id>
    <secondary_id>2013-002416-27</secondary_id>
    <nct_id>NCT02034279</nct_id>
  </id_info>
  <brief_title>The INFECIR-2 Albumin Prevention Study</brief_title>
  <acronym>INFECIR2</acronym>
  <official_title>Albumin Administration in the Prevention of Hepatorenal Syndrome and Death in Patients With Cirrhosis, Bacterial Infections Other Than Spontaneous Bacterial Peritonitis and High Risk of Hospital Mortality</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>EASL - CLIF Consortium</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>EASL - CLIF Consortium</source>
  <oversight_info>
    <authority>Spain: Agencia Española de Medicamentos y Productos Sanitarios</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to evaluate whether  albumin administration improves short-term
      survival in patients with advanced cirrhosis, signs of systemic inflammation and bacterial
      infections other than Spontaneous Bacterial Peritonitis (SBP).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of this study is to evaluate if IV albumin administration improves short-term
      survival in patients with advanced cirrhosis (serum creatinine ≥ 1.2 mg/dl, serum sodium ≤
      130 mEq/l -milliequivalents per liter- and/or serum bilirubin ≥4 mg/dl), signs of systemic
      inflammation and bacterial infections other than spontaneous bacterial peritonitis (urinary
      infection, pneumonia, skin/soft tissue infection, acute cholangitis or suspected bacterial
      infection).

      Primary goals of the study:

      • Effect of albumin administration 28-day survival and in hospital survival (average 2
      weeks).

      Secondary goals of the study:

        -  Effect of albumin administration on 90-day survival.

        -  Effect of albumin administration on the incidence of renal dysfunction, type-1 and 2
           Hepatorenal Syndrome (HRS) during hospitalization.

        -  Effect of albumin on circulatory function estimated by changes in plasma levels of
           renin and noradrenaline and in serum levels of lactate among infection diagnosis, day 3
           and infection resolution.

        -  Effect of albumin on serum levels of interleukin-6 (IL-6), tumor necrosis factor alpha
           (TNF-alpha) and nitric oxide (NOX) and on plasma levels of von Willebrand factor
           (vWF:Ag) at diagnosis and resolution of infection.

        -  Effect of albumin on blood leukocyte count and serum C-reactive protein levels (CRP)
           during infection.

        -  Effect of albumin on the development of other individual organ failures (renal, liver,
           cerebral, circulatory, coagulation and respiratory), acute-on-chronic liver failure
           (ACLF type 1, 2 and 3 according to the Canonic Study), CLIF-SOFA score, CLIF-Consortium
           score, Child-Pugh score and MELD score during hospitalization.

        -  Evaluation of predictive factors of HRS and ACLF development in non-SBP infections.

        -  Samples (blood, plasma, serum and urine) will be obtained and stored for genomic,
           proteomic and standard biochemical investigations in future ancillary studies related
           to the aim of the study.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">March 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>survival</measure>
    <time_frame>28-day survival</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>28-day survival and in hospital survival (expected average 2 weeks) will be the primary outcome</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>survival</measure>
    <time_frame>90-day survival</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Percentage of subjects within each arm that survived at this time point</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal dysfunction</measure>
    <time_frame>hospitalization (expected average 2 weeks)</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>number of participants</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>circulatory dysfunction</measure>
    <time_frame>day 3 and day of infection resolution</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>plasma concentration of hormones</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammation and endothelial function</measure>
    <time_frame>day of infection resolution</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Plasma concentration of citokines</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>subsequent organ failure</measure>
    <time_frame>hospitalization (expected average 2 weeks)</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>number of organ failures</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">512</enrollment>
  <condition>Advanced Chronic Liver Disease</condition>
  <condition>Urinary Infection</condition>
  <condition>Pneumonia</condition>
  <condition>Cholangitis</condition>
  <condition>Other Bacterial Diseases</condition>
  <arm_group>
    <arm_group_label>Intravenous  infusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment arm will received intravenous albumin on day 1 and 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No treatment</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Albumin</intervention_name>
    <arm_group_label>Intravenous  infusion</arm_group_label>
    <other_name>Albutein 20 by Grifols</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Cirrhotic patients with age between 18 and 79 years

          -  Signs of systemic inflammation: at least 1 diagnostic criterion of systemic
             inflammatory response syndrome (SIRS) and serum CRP levels ≥2 mg/dl (20 mg/L). This
             CRP cut-off value has a 82% sensitivity and a 70% specificity for the diagnosis of
             bacterial infection in advanced cirrhosis

          -  Urinary infection, pneumonia, skin/soft tissue infection, acute cholangitis or
             suspected bacterial infection

          -  Analytical data of renal and/or liver dysfunction (serum creatinine ≥ 1.2 mg/dl,
             serum sodium ≤ 130 mEq/l, serum bilirubin ≥4 mg/dl). Patients with pneumonia will
             require the presence of at least 1 of these analytical criteria to be included in the
             study. Patients with urinary infection, skin/soft tissue infection, acute cholangitis
             or suspected bacterial infection will require 2 or more criteria for inclusion

        Exclusion Criteria:

          -  &gt; 48h after infection diagnosis

          -  Pregnancy

          -  Acute or subacute liver failure without underlying cirrhosis

          -  Septic shock

          -  Acute respiratory distress syndrome

          -  Gastrointestinal bleeding in the last 5 days

          -  Biopsy proven severe acute alcoholic hepatitis requiring specific treatment

          -  Type-3 ACLF (defined according to the Canonic Study criteria)

          -  Type-1 HRS (IAC criteria; serum creatinine ≥ 2.5 mg/dl)

          -  Intrinsic nephropathy with renal failure (serum creatinine chronically ≥ 1.5 mg/dl)

          -  Hemodialysis or other renal replacement therapy

          -  Arterial hypertension (systolic blood pressure &gt; 160 mmHg and/or diastolic blood
             pressure &gt; 90 mmHg)

          -  Evidence of current malignancy (except for hepatocellular carcinoma within Milan
             criteria or non-melanocytic skin cancer)

          -  Moderate or severe chronic heart (NYHA class II, III or IV) or pulmonary disease
             (GOLD III or IV)

          -  Severe psychiatric disorders

          -  Immunosuppressive drugs

          -  HIV infection

          -  Contraindications to albumin (allergy, signs of pulmonary edema)

          -  Administration of any dose of IV albumin in the last 10 days

          -  Clinical indication for albumin use at inclusion (spontaneous bacterial peritonitis
             coinfection, large volume paracentesis)

          -  Refusal to participate

          -  Patients who cannot provide prior informed consent and when there is documented
             evidence that the patient has no legal surrogate decision maker and it appears
             unlikely that the patient will regain consciousness or sufficient ability to provide
             delayed informed consent

          -  Physician and team not committed to intensive care if needed.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thierry Gustot</last_name>
    <role>Principal Investigator</role>
    <affiliation>Erasme University Hospital, Brussels, Belgium</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Frederick Nevens</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospitals KU, Leuven, Belgium</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Faouzi Saliba</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Paul Brousse, Villejuif, France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>François Durand</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Beaujon, Clichy, France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Matthias Dollinger</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Ulm, Heidelberg and Tübingen, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stefan Zeuzem</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital of Frankfurt, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alexander Gerbes</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital of Munich, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jonel Trebicka</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital of Bonn, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Henning Gronbaeck</last_name>
    <role>Principal Investigator</role>
    <affiliation>Aarhus University Hospital, Aarhus, Denmark</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Fin Stolze Larsen</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rigshospitalet, University of Copenhagen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Zbigniew Konopski</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oslo University Hospital, Norway</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andrea de Gottardi</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bern University Hospital, Switzerland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Aide McCormick</last_name>
    <role>Principal Investigator</role>
    <affiliation>University College of Dublin, Ireland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rajiv Jalan</last_name>
    <role>Principal Investigator</role>
    <affiliation>University College London, United Kingdom</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mauro Bernardi</last_name>
    <role>Principal Investigator</role>
    <affiliation>Santa Orsola-Malpighi Hospital, Bologna, Italy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Paolo Angeli</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Padova, Italy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Carlo Alessandria</last_name>
    <role>Principal Investigator</role>
    <affiliation>San Giovanni Battista Hospital, University of Turin, Italy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Francesco Salerno</last_name>
    <role>Principal Investigator</role>
    <affiliation>Policlinico IRCCS San Donato, University of Milan, Italy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Agustin Albillos</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Ramon y Cajal, Madrid, Spain</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Juan Cordoba</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Vall d'Hebron, Barcelona, Spain</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Javier Fernandez</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Clinic, Barcelona, Spain</affiliation>
  </overall_official>
  <overall_official>
    <last_name>German Soriano</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Santa Creu i Sant Pau, Barcelona, Spain</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rafael Bañares</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Gregorio Marañon, Madrid, Spain</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jose Luis Montero</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Reina Sofia, Cordoba, Spain</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Manuela Merli</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sapienza University of Rome, Italy</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Javier Fernandez, PhD</last_name>
    <phone>0034932270000</phone>
    <phone_ext>2204</phone_ext>
    <email>jdez@clinic.ub.es</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rita Garcia, PhD</last_name>
    <phone>0034932271826</phone>
    <email>rigarcia@clinic.ub.es</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Clinic</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Javier Fernandez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://www.clifconsortium.com/</url>
  </link>
  <reference>
    <citation>Guevara M, Terra C, Nazar A, Solà E, Fernández J, Pavesi M, Arroyo V, Ginès P. Albumin for bacterial infections other than spontaneous bacterial peritonitis in cirrhosis. A randomized, controlled study. J Hepatol. 2012 Oct;57(4):759-65. doi: 10.1016/j.jhep.2012.06.013. Epub 2012 Jun 23.</citation>
    <PMID>22732511</PMID>
  </reference>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 10, 2014</lastchanged_date>
  <firstreceived_date>January 7, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cirrhosis</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Bacterial Infections</mesh_term>
    <mesh_term>Cholangitis</mesh_term>
    <mesh_term>Hepatorenal Syndrome</mesh_term>
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Urinary Tract Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
